



## CORPORATE PROFILE

A public corporation registered on the  
TSX Venture Exchange under the symbol “NTB” ♦ NASDAQ under the symbol “NEPT”

### OUR MISSION

Neptune develops therapeutic products extracted from marine biomass, using unique process, with clinically proven health benefits patented for worldwide commercialization with strategic partners, in order to contribute to the health and wellness of humans.

### HIGHLIGHTS / STRATEGY

2008/2009 - European, Asian & North American Markets

Regulatory approvals and Market penetration into nutraceutical segments

Three patent families : 34 issued and 66 pending patents in different countries on extraction process and composition of matter/usage

### PRODUCT LINE

#### *New Class of Functional Ingredients*



Marine Phospholipids  
bonding  
EPA, DHA and Antioxidants

**Proprietary Molecular Structure**

### IP and DISCOVERIES

First **animal flavonoid molecule** known to science

**Novel phospholipid molecules** with powerful  
cardiovascular and neurological benefits

### CLINICAL STUDIES

**Highly significant clinical study/results on:**

- ♦ Cardiovascular Health
- ♦ Joint Health
- ♦ Cognitive Function
- ♦ Women's Health
- ♦ Skin Care

## MARKETS

**NUTRACEUTICAL**

**COSMECEUTICAL**

**BIOPHARMACEUTICAL**

**NUTRIGENOMIC**

**AQUACULTURE / ANIMAL FOOD**

## PRINCIPAL DISTRIBUTORS

### NORTH AMERICA

Nature's Way  
Purity Life (Quest)  
Jarrow Formula  
Lalco Laboratory  
Mercola.com  
Threshold  
Schiff Nutrition

### EUROPE

CoralCare  
Nutrisan  
Phytobiolab  
Polaris  
Reflex  
Biocyte

### ASIA/PACIFIC

Azpa International  
Inovail Pharma  
Vital Health Foods  
Maypro

### WORLDWIDE

Croda (N/A Europe)  
Herbalife  
Nu-Skin

## FINANCIAL FIGURES

### FINANCE

(\$'000 Cdn)


	2003	2004	2005	2006	2007	2008 Q3
<b>SALES</b>	614	*2,162	*4,838	*6,912	8 126	7 129
<b>EBITDA</b>	(2,402)	(1,659)	401	1,049	1 504	750

\* Following (2006) EIC-156 Application

**NEPTUNE TOTAL INVESTMENT \$ 22,000,000 Cdn**



TSX-Venture Exchange • Symbol : **NTB**  
NASDAQ • Symbol: **NEPT**  
Shares outstanding: 37,481,796  
Stock price (June 3, 2008): \$Cdn 3,25  
Market Capitalization: \$Cdn 121,815,837



### For Investor Relations

Toni Rinow, Ph.D., MBA

[t.rinow@neptunebiotech.com](mailto:t.rinow@neptunebiotech.com)

John Mills

[John.Mills@icrinc.com](mailto:John.Mills@icrinc.com)



[www.icrinc.com](http://www.icrinc.com)

Tel. 310.954.1100

## MANAGEMENT AND BOARD OF DIRECTORS

### MANAGEMENT

NAME	POSITION
Henri Harland	President & Chief Executive Officer
Dr. Tina Sampalis	Chief Scientific Officer
André Godin	Vice-president, Administration & Finance
Thierry Houillon	Vice-president, Nutraceutical
Dr. Toni Rinow	Corporate Development & Investor Relations
Alain Marchand	Plant Manager
Xavier Harland	Director, Finance
Luc A. Rainville	Director, Scientific Affairs
Dr. Wael Massrieh	Director, R & D

### Administration

225 Promenade du Centropolis, Suite 200, Laval, (Québec) Canada H7T 3B3  
Tel.: +1 450-687-2262 Fax: +1 450-687-2272

Toll free (Canada-USA): 1-888-664-9166

[www.neptunebiotech.com](http://www.neptunebiotech.com) - [info@neptunebiotech.com](mailto:info@neptunebiotech.com)

### Plant

795 Pépin Street, Sherbrooke (Québec) Canada J1L 2P8

### BOARD OF DIRECTORS

NAME	POSITION
Michel Timperio	Chairman, NTB - President & CEO, TBS
Dr. Ronald Denis	Chief of Surgery, Sacré-Cœur Hospital
Michel Chartrand	President, Groupe PharmEssor
Daniel Perry	President, Vivier des Landes (France)
Thierry Houillon	Vice-President, Nutraceutical, NTB
Henri Harland	President & CEO, NTB

### Financial Communication

André Godin, Vice-president, Administration & Finance  
[a.godin@neptunebiotech.com](mailto:a.godin@neptunebiotech.com)

### Scientific Communication

Dr. Tina Sampalis, Chief Scientific Officer  
[t.sampalis@neptunebiotech.com](mailto:t.sampalis@neptunebiotech.com)